0,1,2,3,4,5,6,7
Table 5.3:  Absolute added values of targeted and systematic biopsies for ISUP grade > 2 and > 3 Cancer,,,,,,,
,,ISUP > 2,,,ISUP > 3,,
ISUP grade,,"Cochrane 
meta-
analysis* 
[168]","MRI-FIRST 
trial* [124]","4M trial 
[125]","Cochrane 
meta-
analysis* 
[168]","MRI-FIRST 
trial* [124]","4M trial 
[125]"
Biopsy-naïve,"Added value of 
MRI-TBx","6.3% 
(4.8–8.2)","7.6% 
(4.6–11.6)",7.0% (ND),"4.7%
(3.5–6.3)","6.0% 
(3.4–9.7)",3.2% (ND)
,"Added value 
of systematic 
biopsy","4.3% 
(2.6–6.9)","5.2% 
(2.8–8.7)",5.0% (ND),"2.8% 
(1.7–4.8)","1.2% 
(0.2–3.5)",4.1% (ND)
,"Overall 
prevalence","27.7% 
(23.7–32.6)","37.5% 
(31.4–43.8)",30% (ND),"15.5% 
(12.6–19.5)","21.1% 
(16.2–26.7)",15% (ND)
"Prior negative 
biopsy","Added value of 
MRI-TBx","9.6% 
(7.7–11.8)",-,-,"6.3% 
(5.2–7.7)",-,-
,"Added value of  
systematic biopsy","2.3% 
(1.2–4.5)",-,-,"1.1% 
(0.5–2.6)",-,-
,"Overall 
prevalence","22.8% 
(20.0–26.2)",-,-,"12.6% 
(10.5–15.6)",-,-
